Most importantly using matched tumor samples from melanoma patients before and after development of resistance, we observed that miR-579-3p is strongly downregulated in tumor biopsies from the same patient after the development of resistance and that this coincides with a reciprocal regulation of the expression of its target oncogenes BRAF and MDM-2 [59]. This evidence concerns the gene BRAF and neoplasm.